Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer.
Li-Chung ChiuPing-Chih HsuChin-Chou WangHow-Wen KoAllen Chung-Cheng HuangJia-Shiuan JuPi-Hung TungAllen Chung-Cheng HuangCheng-Ta YangPublished in: Thoracic cancer (2024)
We found that EGFR-mutated NSCLC patients receiving first-line afatinib were prone to shorter PFS if they had distant organ metastasis, especially liver metastasis.